Takanawa Pharma advised as pharmaceutical/healthcare business advisors to GI-Innovation on its collaboration agreement with Maruho for the development and commercialization of GI-301, a novel long-acting lgE Trap-Fc fusion protein for allergic diseases, in Japan.